Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 and Everolimus in Recurrent or Progressive Medulloblastoma
NCT07865130Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jun 2033
- Countries
- 1
01
Overview
Phase 1, open-label trial of rvu120 in medulloblastoma (3 arms). Primary endpoints: Adverse Events, Serious Adverse Events, and Dose-Limiting Toxicities and Maximum Tolerated Dose and/or Recommended Phase 2 Dose. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rvu120
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT07865130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865130.